Yuexinzi Jin

Dr. Yuexinzi Jin


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MYMengyao Yu
Mengyao Yu
YJYuexinzi Jin
Yuexinzi Jin
SZShichang Zhang
Shichang Zhang
JXJian Xu
Jian Xu
JZJiexin Zhang
Jiexin Zhang
Human cytomegalovirus (HCMV) is a double-stranded DNA virus that belongs to the β-herpesvirus family and infects 40–90% of the adult population worldwide. HCMV infection is usually asymptomatic in healthy individuals but causes serious problems in immunocompromised people. We restricted this narrative review (PubMed, January 2022) to demonstrate the interaction and molecular mechanisms between the virus and host immune cells with a focus on HCMV-encoded miRNAs. We found a series of HCMV-encoded miRNAs (e.g., miR-UL112 and miR-UL148D) are explicitly involved in the regulation of viral DNA replication, immune evasion, as well as host cell fate. MiRNA-targeted therapies have been explored for the treatment of atherosclerosis, cardiovascular disease, cancer, diabetes, and hepatitis C virus infection. It is feasible to develop an alternative vaccine to restart peripheral immunity or to inhibit HCMV activity, which may contribute to the antiviral intervention for serious HCMV-related diseases.

Verified
Journal Article
Open access
PDF file
LMLingyao Ma
Lingyao Ma
YJYuexinzi Jin
Yuexinzi Jin
JXJian Xu
Jian Xu
JZJiexin Zhang
Jiexin Zhang
Breast cancer (BC) is the most common cancer in women worldwide. It is one of the main causes of cancer-related mortality. The breast tumor microenvironment (Br-TME) has emerged as an important factor related to BC development and prognosis. Tumor-associated macrophages (TAMs) are the main effector cells in the Br-TME; they play key roles in regulating angiogenesis, immunosuppression, metastasis, and chemoresistance in BC patients. In this review, we introduce the macrophage niche in the Br-TME, particularly emphasizing the origin of TAMs. Next, we summarize the typical pathways and molecular mechanisms of the interactions between TAMs and various other components in the Br-TME. Finally, we provide an overview of drugs that target TAMs and discuss the prevailing technologies for drug delivery in the context of BC treatment. Identification of the dynamic variations in tumor-promoting TAMs will help reveal the key links that drive BC progression. This review provides a theoretical basis for upcoming clinical trials that may substantially benefit patients.

20 July 2026 in Redox Biology
Verified
Journal Article
Open access
TWTing Wang
Ting Wang
LYLina Yan
Lina Yan
XHXi Huang
Xi Huang
LZLingfei Zhou
Lingfei Zhou
YMYepeng Mao
Yepeng Mao
FWFang Wang
Fang Wang
Abnormal lipid accumulation in the tumor microenvironment (TME) promotes lipid peroxidation in tumor-infiltrating CD8+T cells (CD8+TILs), driving their dysfunction and impairing antitumor immunity in ovarian cancer (OC). To elucidate the underlying immunosuppressive mechanisms, we integrated clinical specimens, mouse models, and in-vitro validation. Notably, CD8+TILs from OC patients exhibited pronounced lipid peroxidation signatures. Elevated oxidized low-density lipoprotein (oxLDL) levels were detected in ovarian tumor interstitial fluid (TIF), tumor mass-derived supernatants, and tissue sections, correlating with accelerated peroxidation phenotype in CD8+TILs. Bulk RNA sequencing and experimental validation revealed LOX-1 as the dominant oxLDL receptor in CD8+TILs, where its expression was positively correlated with peroxidation levels and negatively linked to PRF1, GZMB, and IFNG expression. In ID8 mouse OC models, LOX-1 expression and lipid peroxidation in CD8+TILs increased with tumor progression, and LOX-1-neutralizing antibody treatment partially reversed these changes and restored T-cell function. In vitro, LOX-1 blockade reduced oxLDL-induced lipid peroxidation, restored IFN-γ and GZMB production, and downregulated PD-1 expression, whereas LOX-1 overexpression exerted the opposite effects. Notably, the antioxidants, not ferroptosis inhibitors, restored CD8+T cell effector function by suppressing peroxidation. Mechanistically, oxLDL/LOX-1 signaling activated the transcription factor ELF3, which subsequently bound to the PDCD1 promoter to drive PD-1 expression. Together, this study demonstrates that in CD8+TILs, LOX-1-mediated uptake of oxLDL induced lipid peroxidation via oxidative stress and establish the oxLDL/LOX-1 axis as a pivotal pathway through which lipid peroxidation impairs CD8+TILs function in OC. Targeting LOX-1 or employing antioxidants restored the antitumor capacity of CD8+TILs, providing a mechanistic basis for metabolically modulating T cell-based cancer immunotherapy.

Verified
Journal Article
Open access
PDF file
YJYuexinzi Jin
Yuexinzi Jin
YMYuan Mu
Yuan Mu
LWLi Wang
Li Wang
BZBingfeng Zhang
Bingfeng Zhang
SGSuli Ge
Suli Ge
JZJiexin Zhang
Jiexin Zhang
Accurate measurement of serum uric acid (UA) is critical for disease assessment and therapeutic monitoring; however, numerous factors can compromise the accuracy of UA detection. This study describes a novel circulating immunoglobulin M (IgM)-involved protein complex that interferes with the uricase method and reduces serum UA measurement accuracy. A total of 24 serum samples were collected from 18 patients, and complete clinical information and laboratory data were obtained. Samples were divided into three groups according to their UA reaction curves. Optical density values were extracted to analyze differential insoluble properties, serum viscosity was measured, coimmunoprecipitation was performed for IgM complex detection, and three additional clinical methodologies were used for UA measurement and comparison. All samples exhibiting unique reaction curves showed simultaneous elevations in IgM and complement component 4 (C4) levels. Circulating IgM formed a protein complex with C4d without significantly increasing serum viscosity. The insolubility of the IgM–C4d complex was attributable to the particular alkaline component of the uricase reagent. Inaccurate UA measurements could only be corrected by mass spectrometry. This study represents the first report of the circulating IgM–C4d protein complex. Given that serum UA serves as a crucial therapeutic indicator for specific patient populations, mass spectrometry is the preferred analytical method for accurate UA quantification in these individuals.